On August 8, 2023 Plus Therapeutics, Inc. (Nasdaq: PSTV) (the "Company"), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous system cancers, reported a key opinion leader roundtable discussion to be held on Friday, August 11, 2023, 8:00 a.m. – 9:00 a.m. ET to discuss the latest data from the ReSPECT-LM clinical trial of rhenium (186Re) obisbemeda that will be presented at the Society for Neuro Oncology (SNO)/American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Central Nervous System (CNS) Cancer Conference on August 10, 2023 (Press release, PLUS THERAPEUTICS, AUG 8, 2023, View Source;_hsmi=269509104&_hsenc=p2ANqtz-89_OBvNFnW0uugglRG4wRRBcKdiDIT1INGLN7Tn-CIPCJ9ScMxixrB48kxKd8Uu3vpBKS9BMOI04QHVJaIree6xQ-Bfw&utm_content=269509104&utm_source=hs_email [SID1234634006]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The webinar will feature a comprehensive discussion about the ongoing ReSPECT-LM Phase 1/2a dose escalation clinical trial, including key safety, tolerability, dosing, feasibility and efficacy data. Speakers include:
Andrew J. Brenner, M.D., Ph.D., Professor of Medicine, Neurology, and Neurosurgery at The University of Texas, Health Services Center at San Antonio and principal investigator of the ReSPECT-GBM trial and co-principal investigator of the ReSPECT-LM trial.
Priya Kumthekar, M.D., Associate Professor of Neurology and Medicine (Hematology and Oncology) at Northwestern University’s Feinberg School of Medicine and co-principal investigator of the ReSPECT-LM trial.
Marc H. Hedrick, M.D., President and Chief Executive Officer of Plus Therapeutics
Justin Walsh, Ph.D., Senior Healthcare Analyst, Jones Research will moderate the roundtable and in addition will provide an overview of the radiotherapeutic market.
Webcast Details
A webinar with accompanying slides will be available in the Events page of the Investor Relations section of the Plus Therapeutics website beginning Friday, August 11, 2023 at 8:00 a.m. ET. Participants may also pre-register any time before the call here. Please access the webinar 15 minutes prior to the start time.
The webinar will be available on the Company’s website under the ‘For Investor’ section. The webcast will be available on the Company’s website for 90 days following the live call.